

## MOLECULAR SIGNATURE TEST

Sample Patient Report

### HEALTHCARE PROVIDER

**Name:** Rachel Smith  
**Requisition No.:** 0000000001  
**Collection Date:** 02/05/2025  
**Specimen Received:** 02/06/2025 10:30:17  
**Report Date:** 02/09/2025

### CLINIC

**Clinic Name:** Community  
 Rheumatology Clinic  
**Address:** 34 Main St. Ste 200  
 Boston, MA 02110  
**Phone:** (617) 111-1234  
**Fax:** +16172225678

### PATIENT

**Name:** Diana Johnson  
**DOB:** 1/23/1969 **Sex:** F  
**Weight:** 150.00 lbs  
**Height:** 5.00' 7.00"  
**Patient Global Assessment:** 50


### PrismRA RESULT

#### PrismRA TNFi Result:

**TNFi Inadequate  
 Response Signature  
 Detected**

This patient has a  
 PrismRA Score of **14.2**

#### Interpretative Criteria:



**Patient has a 10% chance of  
 responding to a TNFi**

**≥10.6:** Patient has a high signal of  
 inadequate response to TNFi therapies

### PrismRA SCORE INTERPRETATION

A patient with a PrismRA Score  $\geq 10.6$  has a molecular signature of inadequate response to TNFi therapies. This corresponds to an approximate 90% chance of inadequately responding to TNFi therapies. Thus, this patient has an approximate 10% chance of responding to TNFi therapies.

### TEST DESCRIPTION

**PrismRA** PrismRA is a molecular signature response classifier (MSRC) that uses gene expression features, clinical features, and anti-cyclic citrullinated protein (anti-CCP) antibody to detect a signature of non-response to tumor necrosis factor- $\alpha$  inhibitors (TNFi) for patients with rheumatoid arthritis. PrismRA predicts the patient's likelihood of inadequately responding to all TNFi therapies.

Total RNA was extracted from PAXgene® whole blood sample and sequenced at Ambry Genetics. The extracted RNA samples were quantified and had their RNA integrity determined. RNA was sheared, cDNA converted, and library prepared via hybrid capture. After library amplification, samples were sequenced on a NovaSeq 6000 (Illumina). Anti-CCP antibody measurements were performed at Scipher using in vitro semi-quantitative determination of human IgG autoantibodies to cyclic citrullinated peptides in human serum. Final algorithmic analysis was performed at Scipher with PrismRA pipeline v1.1.02. The PrismRA result is reported on a continuous 1 to 25 scale. The higher the score, the more likely the patient will have an inadequate response to TNFi therapies; the lower the score, the less likely the patient will have an inadequate response to TNFi therapies. However, a low score does not ensure a positive response to TNFi therapies. Response is defined as achieving ACR50 at 6 months.

### COMMENTS

The PrismRA result is intended for informational purposes only and does not constitute a recommendation. Medical management decisions should be made by a healthcare provider with the full medical history and clinical assessment of the patient. The PrismRA test is intended for clinical use. This test was developed and its performance characteristics determined by Scipher Medicine. It has not been cleared or approved by the US Food and Drug Administration. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical testing. For full test specification and related publications please visit [www.PrismRA.com](http://www.PrismRA.com).

**Laboratory CLIA Number:** 34D2180776  
**Laboratory CAP Number:** 8821838

**Laboratory Directors:**  
 Sarah Rapisardo, PhD, FACMG

Sarah Rapisardo